Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | XBP1 | P17861 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540128 | 1.00 | MAPT (1.00) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL13366830 | 0.97 | RAB9A (0.94) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL13366895 | 0.97 | RAB9A (0.94) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL60258 | 0.97 | RAB9A (0.94) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL61215 | 0.97 | RAB9A (0.94) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL13366900 | 0.97 | RAB9A (0.94) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL12260315 | 0.85 | MAPT (0.74) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL20302805 | 0.85 | SMN1; SMN2 (0.74) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL20302771 | 0.84 | KDM4E (0.78) | MAPTRAB9AKDM4EPOLBTSHR | |
| SCHEMBL20302744 | 0.83 | KDM4E (0.71) | MAPTRAB9AKDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119894533-A | Methods and compositions for activating, modulating and regulating weight loss and therapeutic uses thereof | 科吉恩治疗股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| EP-4536285-A2 | METHODS AND COMPOSITIONS FOR INITIATING, REGULATING, AND MODULATING WEIGHT LOSS AND THERAPEUTIC APPLICATIONS THEREOF | Kojin Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| US-12213977-B2 | Methods and compositions for treating melanoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-04 | — | — | US | claimed |
| WO-2024233348-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES BY TARGETING PHOSPHOLIPIDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4460299-A2 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2023240204-A2 | METHODS AND COMPOSITIONS FOR INITIATING, REGULATING, AND MODULATING WEIGHT LOSS AND THERAPEUTIC APPLICATIONS THEREOF | Kojin Therapeutics, Inc. (US) | 2023-12-14 | — | — | WO | claimed |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2023-12-12 | — | — | US | claimed |
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. | 2023-07-20 | — | — | US | claimed |
| WO-2023133053-A2 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | claimed |
| US-20230035422-A1 | METHODS FOR TREATING DISEASES BY TARGETING ONCOGENIC LIPIDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-02-02 | — | — | US | claimed |
| US-11541116-B1 | Methods and compositions for inducing ferroptosis in vivo | Kojin Therapeutics, Inc. (US) | 2023-01-03 | — | — | US | claimed |
| US-20220412989-A1 | COMPOSITIONS AND METHODS FOR DETECTING CELLS UNDERGOING FERROPTOSIS USING AN ANTIBODY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-29 | — | — | US | claimed |
| US-11499978-B2 | Method for measuring quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2022-11-15 | — | — | US | claimed |
| US-20220193047-A1 | METHODS OF ENHANCING RADIOTHERAPY USING FERROPTOSIS INDUCERS AS RADIOSENSITIZERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-23 | — | — | US | claimed |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | UNIV TEXAS (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000740-A1 | USE OF A L-ASPARAGINASE IN COMBINATION WITH A FERROPTOSIS INDUCER FOR THE TREATMENT OF EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA | INST NAT SANTE RECH MED (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20220233535-A1 | USE OF INHIBITORS OF YAP/TAZ FOR THE TREATMENT OF CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-07-28 | — | — | US | disclosed |
| US-20220228110-A1 | EXPRESSION VECTORS, METHODS FOR SCREENING HOST CELLS EXPRESSING TARGET PROTEINS, AND METHODS FOR ESTABLISHING CELL LINES STABLY EXPRESSING FOREIGN RECOMBINANT GENES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2022-07-21 | — | — | US | disclosed |
| US-20220193047-A1 | METHODS OF ENHANCING RADIOTHERAPY USING FERROPTOSIS INDUCERS AS RADIOSENSITIZERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11499978-B2 | Method for measuring quality of therapeutic cell through real-time glutathione measurement | GGT1, GSR, GPX1 | MAPT 3287/4885RAB9A 2806/4885KDM4E 3452/4885 |
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | AIFM2, GPX4, SLC40A1 | MAPT 4507/4885RAB9A 3356/4885KDM4E 4110/4885 |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | GSR, GPX1, GGT1 | MAPT 3274/4885RAB9A 2764/4885KDM4E 3439/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | MAPT 4831/4885RAB9A 2322/4885KDM4E 2580/4885 |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | BRCA1, GPX4, GPX1 | MAPT 4120/4885RAB9A 4561/4885KDM4E 1087/4885 |
| US-20260000740-A1 | USE OF A L-ASPARAGINASE IN COMBINATION WITH A FERROPTOSIS INDUCER FOR THE TREATMENT OF EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA | ERAP1, AIFM2, ERAL1 | MAPT 4764/4885RAB9A 2795/4885KDM4E 199/4885 |
| US-11541116-B1 | Methods and compositions for inducing ferroptosis in vivo | AIFM2, GPX4, SLC40A1 | MAPT 4507/4885RAB9A 3356/4885KDM4E 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.